Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+7.44%
$283.94
100% positive prob.
5-Day Prediction
+10.59%
$292.24
100% positive prob.
20-Day Prediction
+8.45%
$286.61
95% positive prob.
SEC 8-K filings with transcript text
Feb 4, 2026 · 99% conf.
1D
+7.44%
$283.94
Act: -7.74%
5D
+10.59%
$292.24
Act: -7.87%
20D
+8.45%
$286.61
Act: -9.75%
ste-202602040001757898Dublin 2,falseD02 R2962026-02-04353001-38848L2falsefalsefalse00017578982026-02-042026-02-0400017578982025-11-052025-11-050001757898ste:OrdinarySharesMember2026-02-042026-02-040001757898ste:STETwo700SeniorNotesDue2031MemberMember2026-02-042026-02-040001757898ste:Two700SeniorNotesDue2051MemberMember2026-02-042026-02-04
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2026
STERIS plc (Exact Name of Registrant as Specified in Charter)
Ireland001-38848 98-1455064 (State or other jurisdiction of incorporation or organization)(Commission File Number)(IRS Employer Identification No.)
70 Sir John Rogerson's Quay,Dublin 2,IrelandD02 R296 (Address of principal executive offices)
Registrant’s telephone number, including area code: + 353 1 232 2000
Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary Shares, $0.001 par valueSTENew York Stock Exchange 2.700% Senior Notes due 2031STE/31New York Stock Exchange 3.750% Senior Notes due 2051STE/51New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On February 4, 2026, STERIS plc (the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. Description 99.1 Press Release issued by STERIS plc on February 4, 2026 announcing financial results for its fiscal 2026 third quarter ending December 31, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STERIS plc
By /s/ J. Adam Zangerle Name: J. Adam Zangerle Title: Senior Vice President, General Counsel & Company Secretary
Dated: February 4, 2026
Nov 5, 2025
ste-202511050001757898Dublin 2,falseD02 R2962025-11-05353001-38848L2falsefalsefalse00017578982025-11-052025-11-050001757898ste:OrdinarySharesMember2025-11-052025-11-050001757898ste:STETwo700SeniorNotesDue2031MemberMember2025-11-052025-11-050001757898ste:Two700SeniorNotesDue2051MemberMember2025-11-052025-11-05
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025
STERIS plc (Exact Name of Registrant as Specified in Charter)
Ireland001-38848 98-1455064 (State or other jurisdiction of incorporation or organization)(Commission File Number)(IRS Employer Identification No.)
70 Sir John Rogerson's Quay,Dublin 2,IrelandD02 R296 (Address of principal executive offices)
Registrant’s telephone number, including area code: + 353 1 232 2000
Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary Shares, $0.001 par valueSTENew York Stock Exchange 2.700% Senior Notes due 2031STE/31New York Stock Exchange 3.750% Senior Notes due 2051STE/51New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On November 5, 2025, STERIS plc (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. Description 99.1 Press Release issued by STERIS plc on November 5, 2025 announcing financial results for its fiscal 2026 second quarter ending September 30, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STERIS plc
By /s/ J. Adam Zangerle Name: J. Adam Zangerle Title: Senior Vice President, General Counsel & Company Secretary
Dated: November 5, 2025
Aug 6, 2025
ste-202507310001757898Dublin 2,falseD02 R2962025-07-31353001-38848L2falsefalsefalse00017578982025-07-312025-07-310001757898ste:OrdinarySharesMember2025-07-312025-07-310001757898ste:STETwo700SeniorNotesDue2031MemberMember2025-07-312025-07-310001757898ste:Two700SeniorNotesDue2051MemberMember2025-07-312025-07-31
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025
STERIS plc (Exact Name of Registrant as Specified in Charter)
Ireland001-38848 98-1455064 (State or other jurisdiction of incorporation or organization)(Commission File Number)(IRS Employer Identification No.)
70 Sir John Rogerson's Quay,Dublin 2,IrelandD02 R296 (Address of principal executive offices)
Registrant’s telephone number, including area code: + 353 1 232 2000
Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary Shares, $0.001 par valueSTENew York Stock Exchange 2.700% Senior Notes due 2031STE/31New York Stock Exchange 3.750% Senior Notes due 2051STE/51New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On August 6, 2025, STERIS plc (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Chief Financial Officer
On July 31, 2025, Michael J. Tokich notified the Board of Directors (the “Board”) of his resignation from his current role as Senior Vice President and Chief Financial Officer of the Company.
Mr. Tokich and the Company have entered into a Transition Agreement, dated August 5, 2025 (the “Transition Agreement”). The Transition Agreement will take effect on August 18, 2025. The Transition Agreement provides for a continuation of Mr. Tokich’s employment with the Company as a senior financial advisor until March 31, 2026 (the “Senior Advisor Period”), subject to potential termination by the Company for “Cause” or because of Mr. Tokich’s death or “Disability” (“Cause” and “Disability” used as defined in the Transition Agreement), by the Company after January 1, 2026 for any reason or by Mr. Tokich at any time for any reason. The Transition Agreement further provides that during the Senior Advisor Period, Mr. Tokich’s annual base salary rate will be reduced to $427,450.14 but his other outstanding awards will remain in place (including his bonus target under the Company’s Management and Incentive Compensation Plan (“MICP”) at his previous salary rate). Subject to the terms of the Transition Agreement, Mr. Tokich’s outstanding but unvested equity awards granted in October 2021 and June 2022 will continue to vest and be eligible for continued “retirement” vesting and exercisability on the same terms as similar equity awards made subsequent to May 30, 2023. The Company, at its sole discretion, may extend the Senior Advisor Period by up to s
This page provides STERIS plc (Ireland) (STE) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on STE's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.